Skip to main content
Erschienen in: Breast Cancer 3/2017

02.08.2016 | Original Article

Feasibility and potential limitations of abbreviated breast MRI: an observer study using an enriched cohort

verfasst von: Youichi Machida, Akiko Shimauchi, Yoshihide Kanemaki, Takao Igarashi, Marie Harada, Eisuke Fukuma

Erschienen in: Breast Cancer | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Breast cancer screening using magnetic resonance imaging (MRI) has been introduced in Western countries primarily for populations with an elevated risk of breast cancer. We conducted an observer study involving an experimental abbreviated MRI interpretation by Japanese radiologists, using an enriched cohort, to evaluate its feasibility in a screening setting.

Methods

Eighty-eight breast MRI examinations including 28 cases with breast cancer were enrolled as study subjects. Two radiologists independently reviewed the MR images, first with only two sequences (abbreviated series), and then with all of the images provided for clinical care (full diagnostic series). The difference in sensitivity and specificity was evaluated using McNemar’s test. Interobserver agreement was assessed by calculating κ values.

Results

A total of 176 breasts including 31 cancers (3 cases with bilateral disease) were included. No significant difference in sensitivity or specificity for either observer was observed between the abbreviated series and the full diagnostic series (observer 1: sensitivity 87.1 vs 87.1 %, p = 1.00, specificity 91.7 vs 90.3 %, p = 0.791; observer 2: sensitivity 93.5 vs 96.8 %, p = 1.00, specificity 83.4 vs 89.7 %, p = 0.064). Moderate interobserver agreement (κ = 0.56) was observed for the abbreviated series, whereas substantial agreement (κ = 0.69) was observed for the full diagnostic series.

Conclusions

The diagnostic accuracy of the abbreviated breast MRI was not inferior to that of the conventional full diagnostic interpretation, although a slight decline in interobserver agreement was observed.
Literatur
1.
Zurück zum Zitat Tabar L, Fagerberg CJ, Gad A, Baldetorp L, Holmberg LH, Grontoft O, et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet. 1985;1:829–32.CrossRefPubMed Tabar L, Fagerberg CJ, Gad A, Baldetorp L, Holmberg LH, Grontoft O, et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet. 1985;1:829–32.CrossRefPubMed
2.
Zurück zum Zitat Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 2007;356:227–36.CrossRefPubMed Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 2007;356:227–36.CrossRefPubMed
3.
Zurück zum Zitat Buist DS, Porter PL, Lehman C, Taplin SH, White E. Factors contributing to mammography failure in women aged 40–49 years. J Natl Cancer Inst. 2004;96:1432–40.CrossRefPubMed Buist DS, Porter PL, Lehman C, Taplin SH, White E. Factors contributing to mammography failure in women aged 40–49 years. J Natl Cancer Inst. 2004;96:1432–40.CrossRefPubMed
4.
Zurück zum Zitat Mandelson MT, Oestreicher N, Porter PL, White D, Finder CA, Taplin SH, et al. Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst. 2000;92:1081–7.CrossRefPubMed Mandelson MT, Oestreicher N, Porter PL, White D, Finder CA, Taplin SH, et al. Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst. 2000;92:1081–7.CrossRefPubMed
5.
Zurück zum Zitat Carney PA, Miglioretti DL, Yankaskas BC, Kerlikowske K, Rosenberg R, Rutter CM, et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med. 2003;138:168–75.CrossRefPubMed Carney PA, Miglioretti DL, Yankaskas BC, Kerlikowske K, Rosenberg R, Rutter CM, et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med. 2003;138:168–75.CrossRefPubMed
7.
Zurück zum Zitat Orel SG, Schnall MD. MR imaging of the breast for the detection, diagnosis, and staging of breast cancer. Radiology. 2001;220:13–30.CrossRefPubMed Orel SG, Schnall MD. MR imaging of the breast for the detection, diagnosis, and staging of breast cancer. Radiology. 2001;220:13–30.CrossRefPubMed
9.
Zurück zum Zitat Lehman CD, Gatsonis C, Kuhl CK, Hendrick RE, Pisano ED, Hanna L, et al. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med. 2007;356:1295–303.CrossRefPubMed Lehman CD, Gatsonis C, Kuhl CK, Hendrick RE, Pisano ED, Hanna L, et al. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med. 2007;356:1295–303.CrossRefPubMed
10.
Zurück zum Zitat Riedl CC, Luft N, Bernhart C, Weber M, Bernathova M, Tea MK, et al. Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density. J Clin Oncol. 2015;33:1128–35.CrossRefPubMed Riedl CC, Luft N, Bernhart C, Weber M, Bernathova M, Tea MK, et al. Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density. J Clin Oncol. 2015;33:1128–35.CrossRefPubMed
11.
Zurück zum Zitat Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004;351:427–37.CrossRefPubMed Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004;351:427–37.CrossRefPubMed
12.
Zurück zum Zitat Kuhl C, Weigel S, Schrading S, Arand B, Bieling H, Konig R, et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol. 2010;28:1450–7.CrossRefPubMed Kuhl C, Weigel S, Schrading S, Arand B, Bieling H, Konig R, et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol. 2010;28:1450–7.CrossRefPubMed
13.
Zurück zum Zitat Kuhl CK, Schrading S, Leutner CC, Morakkabati-Spitz N, Wardelmann E, Fimmers R, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol. 2005;23:8469–76.CrossRefPubMed Kuhl CK, Schrading S, Leutner CC, Morakkabati-Spitz N, Wardelmann E, Fimmers R, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol. 2005;23:8469–76.CrossRefPubMed
14.
Zurück zum Zitat Lehman CD, Blume JD, Weatherall P, Thickman D, Hylton N, Warner E, et al. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer. 2005;103:1898–905.CrossRefPubMed Lehman CD, Blume JD, Weatherall P, Thickman D, Hylton N, Warner E, et al. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer. 2005;103:1898–905.CrossRefPubMed
15.
Zurück zum Zitat Sardanelli F, Podo F. Breast MR imaging in women at high-risk of breast cancer. Is something changing in early breast cancer detection? Eur Radiol. 2007;17:873–87.CrossRefPubMed Sardanelli F, Podo F. Breast MR imaging in women at high-risk of breast cancer. Is something changing in early breast cancer detection? Eur Radiol. 2007;17:873–87.CrossRefPubMed
16.
Zurück zum Zitat Tilanus-Linthorst MM, Obdeijn IM, Bartels KC, de Koning HJ, Oudkerk M. First experiences in screening women at high risk for breast cancer with MR imaging. Breast Cancer Res Treat. 2000;63:53–60.CrossRefPubMed Tilanus-Linthorst MM, Obdeijn IM, Bartels KC, de Koning HJ, Oudkerk M. First experiences in screening women at high risk for breast cancer with MR imaging. Breast Cancer Res Treat. 2000;63:53–60.CrossRefPubMed
17.
Zurück zum Zitat Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004;292:1317–25.CrossRefPubMed Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004;292:1317–25.CrossRefPubMed
18.
Zurück zum Zitat Kuhl CK, Schrading S, Strobel K, Schild HH, Hilgers RD, Bieling HB. Abbreviated breast magnetic resonance imaging (MRI): first postcontrast subtracted images and maximum-intensity projection-a novel approach to breast cancer screening with MRI. J Clin Oncol. 2014;32:2304–10.CrossRefPubMed Kuhl CK, Schrading S, Strobel K, Schild HH, Hilgers RD, Bieling HB. Abbreviated breast magnetic resonance imaging (MRI): first postcontrast subtracted images and maximum-intensity projection-a novel approach to breast cancer screening with MRI. J Clin Oncol. 2014;32:2304–10.CrossRefPubMed
19.
Zurück zum Zitat Bickelhaupt S, Laun FB, Tesdorff J, Lederer W, Daniel H, Stieber A, et al. Fast and noninvasive characterization of suspicious lesions detected at breast cancer X-ray screening: capability of diffusion-weighted MR imaging with MIPs. Radiology. 2015:150425. Bickelhaupt S, Laun FB, Tesdorff J, Lederer W, Daniel H, Stieber A, et al. Fast and noninvasive characterization of suspicious lesions detected at breast cancer X-ray screening: capability of diffusion-weighted MR imaging with MIPs. Radiology. 2015:150425.
20.
Zurück zum Zitat Grimm LJ, Soo MS, Yoon S, Kim C, Ghate SV, Johnson KS. Abbreviated screening protocol for breast MRI: a feasibility study. Acad Radiol. 2015;22:1157–62.CrossRefPubMed Grimm LJ, Soo MS, Yoon S, Kim C, Ghate SV, Johnson KS. Abbreviated screening protocol for breast MRI: a feasibility study. Acad Radiol. 2015;22:1157–62.CrossRefPubMed
21.
Zurück zum Zitat Harvey SC, Di Carlo PA, Lee B, Obadina E, Sippo D, Mullen L. An abbreviated protocol for high-risk screening breast MRI saves time and resources. J Am Coll Radiol. 2016;13:374–80.CrossRefPubMed Harvey SC, Di Carlo PA, Lee B, Obadina E, Sippo D, Mullen L. An abbreviated protocol for high-risk screening breast MRI saves time and resources. J Am Coll Radiol. 2016;13:374–80.CrossRefPubMed
22.
Zurück zum Zitat Heacock L, Melsaether AN, Heller SL, Gao Y, Pysarenko KM, Babb JS, et al. Evaluation of a known breast cancer using an abbreviated breast MRI protocol: correlation of imaging characteristics and pathology with lesion detection and conspicuity. Eur J Radiol. 2016;85:815–23.CrossRefPubMed Heacock L, Melsaether AN, Heller SL, Gao Y, Pysarenko KM, Babb JS, et al. Evaluation of a known breast cancer using an abbreviated breast MRI protocol: correlation of imaging characteristics and pathology with lesion detection and conspicuity. Eur J Radiol. 2016;85:815–23.CrossRefPubMed
23.
Zurück zum Zitat Mango VL, Morris EA, David Dershaw D, Abramson A, Fry C, Moskowitz CS, et al. Abbreviated protocol for breast MRI: are multiple sequences needed for cancer detection? Eur J Radiol. 2015;84:65–70.CrossRefPubMed Mango VL, Morris EA, David Dershaw D, Abramson A, Fry C, Moskowitz CS, et al. Abbreviated protocol for breast MRI: are multiple sequences needed for cancer detection? Eur J Radiol. 2015;84:65–70.CrossRefPubMed
24.
Zurück zum Zitat Moschetta M, Telegrafo M, Rella L, Stabile Ianora AA, Angelelli G. Abbreviated combined mr protocol: a new faster strategy for characterizing breast lesions. Clin Breast Cancer. 2016;16:207–11.CrossRefPubMed Moschetta M, Telegrafo M, Rella L, Stabile Ianora AA, Angelelli G. Abbreviated combined mr protocol: a new faster strategy for characterizing breast lesions. Clin Breast Cancer. 2016;16:207–11.CrossRefPubMed
25.
Zurück zum Zitat ACR BI-RADS atlas: Breast imaging reporting and data system: mammography, ultrasound, magnetic resonance imaging, follow-up and outcome monitoring, data dictionary. 5th ed. American College of Radiology; 2013. ACR BI-RADS atlas: Breast imaging reporting and data system: mammography, ultrasound, magnetic resonance imaging, follow-up and outcome monitoring, data dictionary. 5th ed. American College of Radiology; 2013.
Metadaten
Titel
Feasibility and potential limitations of abbreviated breast MRI: an observer study using an enriched cohort
verfasst von
Youichi Machida
Akiko Shimauchi
Yoshihide Kanemaki
Takao Igarashi
Marie Harada
Eisuke Fukuma
Publikationsdatum
02.08.2016
Verlag
Springer Japan
Erschienen in
Breast Cancer / Ausgabe 3/2017
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-016-0718-z

Weitere Artikel der Ausgabe 3/2017

Breast Cancer 3/2017 Zur Ausgabe

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.